SCHEMBL1447760

SCHEMBL1447760

COc1cc(O)ccc1C(=O)N1CCOCC1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 2/20 0.61
LMNA P02545 2/20 0.56
GAA P10253 2/20 0.56
MAPT P10636 1/20 0.56
GFER P55789 1/20 0.56
KMT2A Q03164 3/20 0.54
GLA P06280 1/20 0.54
TYR P14679 1/20 0.53
TSHR P16473 2/20 0.53
NPSR1 Q6W5P4 1/20 0.52
HPGD P15428 1/20 0.51
CHEK1 O14757 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
MEN1 O00255 1/20 0.50
POLB P06746 1/20 0.49
PKM P14618 1/20 0.49
APP P05067 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4109352 0.86 ALDH1A1 (0.61) KDM4EALDH1A1LMNAGAAKMT2A
SCHEMBL30073423 0.84 KMT2A (0.60) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL15651032 0.84 ALDH1A1 (0.60) KDM4EALDH1A1LMNAGAAKMT2A
SCHEMBL15285967 0.84 KMT2A (0.60) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL1447972 0.84 ALDH1A1 (0.63) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL7401283 0.84 LMNA (0.54) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL19431552 0.83 LMNA (0.53) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL15317652 0.82 ALDH1A1 (0.57) KDM4EALDH1A1LMNAGAAKMT2A
SCHEMBL19651842 0.82 ALDH1A1 (0.57) KDM4EALDH1A1LMNAGAAKMT2A
SCHEMBL12766946 0.81 HTT (0.72) KDM4EALDH1A1GAAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2301928-A1 Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders AstraZeneca AB (SE) 2011-03-30 EP disclosed
US-20080280906-A1 Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders ASTRAZENECA AB (SE) 2008-11-13 US disclosed
EP-1912974-A1 IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2008-04-23 EP disclosed
WO-2007015064-A1 IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280906-A1 Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders CCNI, MKI67, TYMP KDM4E 3188/4885ALDH1A1 423/4885LMNA 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.